UniProt ID | PML_HUMAN | |
---|---|---|
UniProt AC | P29590 | |
Protein Name | Protein PML | |
Gene Name | PML | |
Organism | Homo sapiens (Human). | |
Sequence Length | 882 | |
Subcellular Localization |
Nucleus. Nucleus, nucleoplasm. Cytoplasm. Nucleus, PML body . Nucleus, nucleolus. Endoplasmic reticulum membrane Peripheral membrane protein Cytoplasmic side. Early endosome membrane Peripheral membrane protein Cytoplasmic side. Isoform PML-1 can |
|
Protein Description | Functions via its association with PML-nuclear bodies (PML-NBs) in a wide range of important cellular processes, including tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense mechanisms. Acts as the scaffold of PML-NBs allowing other proteins to shuttle in and out, a process which is regulated by SUMO-mediated modifications and interactions. Isoform PML-4 has a multifaceted role in the regulation of apoptosis and growth suppression: activates RB1 and inhibits AKT1 via interactions with PP1 and PP2A phosphatases respectively, negatively affects the PI3K pathway by inhibiting MTOR and activating PTEN, and positively regulates p53/TP53 by acting at different levels (by promoting its acetylation and phosphorylation and by inhibiting its MDM2-dependent degradation). Isoform PML-4 also: acts as a transcriptional repressor of TBX2 during cellular senescence and the repression is dependent on a functional RBL2/E2F4 repressor complex, regulates double-strand break repair in gamma-irradiation-induced DNA damage responses via its interaction with WRN, acts as a negative regulator of telomerase by interacting with TERT, and regulates PER2 nuclear localization and circadian function. Isoform PML-6 inhibits specifically the activity of the tetrameric form of PKM. The nuclear isoforms (isoform PML-1, isoform PML-2, isoform PML-3, isoform PML-4 and isoform PML-5) in concert with SATB1 are involved in local chromatin-loop remodeling and gene expression regulation at the MHC-I locus. Isoform PML-2 is required for efficient IFN-gamma induced MHC II gene transcription via regulation of CIITA. Cytoplasmic PML is involved in the regulation of the TGF-beta signaling pathway. PML also regulates transcription activity of ELF4 and can act as an important mediator for TNF-alpha- and IFN-alpha-mediated inhibition of endothelial cell network formation and migration.; Exhibits antiviral activity against both DNA and RNA viruses. The antiviral activity can involve one or several isoform(s) and can be enhanced by the permanent PML-NB-associated protein DAXX or by the recruitment of p53/TP53 within these structures. Isoform PML-4 restricts varicella zoster virus (VZV) via sequestration of virion capsids in PML-NBs thereby preventing their nuclear egress and inhibiting formation of infectious virus particles. The sumoylated isoform PML-4 restricts rabies virus by inhibiting viral mRNA and protein synthesis. The cytoplasmic isoform PML-14 can restrict herpes simplex virus-1 (HHV-1) replication by sequestering the viral E3 ubiquitin-protein ligase ICP0 in the cytoplasm. Isoform PML-6 shows restriction activity towards human cytomegalovirus (HCMV) and influenza A virus strains PR8(H1N1) and ST364(H3N2). Sumoylated isoform PML-4 and isoform PML-12 show antiviral activity against encephalomyocarditis virus (EMCV) by promoting nuclear sequestration of viral polymerase (P3D-POL) within PML NBs. Isoform PML-3 exhibits antiviral activity against poliovirus by inducing apoptosis in infected cells through the recruitment and the activation of p53/TP53 in the PML-NBs. Isoform PML-3 represses human foamy virus (HFV) transcription by complexing the HFV transactivator, bel1/tas, preventing its binding to viral DNA. PML may positively regulate infectious hepatitis C viral (HCV) production and isoform PML-2 may enhance adenovirus transcription.. | |
Protein Sequence | MEPAPARSPRPQQDPARPQEPTMPPPETPSEGRQPSPSPSPTERAPASEEEFQFLRCQQCQAEAKCPKLLPCLHTLCSGCLEASGMQCPICQAPWPLGADTPALDNVFFESLQRRLSVYRQIVDAQAVCTRCKESADFWCFECEQLLCAKCFEAHQWFLKHEARPLAELRNQSVREFLDGTRKTNNIFCSNPNHRTPTLTSIYCRGCSKPLCCSCALLDSSHSELKCDISAEIQQRQEELDAMTQALQEQDSAFGAVHAQMHAAVGQLGRARAETEELIRERVRQVVAHVRAQERELLEAVDARYQRDYEEMASRLGRLDAVLQRIRTGSALVQRMKCYASDQEVLDMHGFLRQALCRLRQEEPQSLQAAVRTDGFDEFKVRLQDLSSCITQGKDAAVSKKASPEAASTPRDPIDVDLPEEAERVKAQVQALGLAEAQPMAVVQSVPGAHPVPVYAFSIKGPSYGEDVSNTTTAQKRKCSQTQCPRKVIKMESEEGKEARLARSSPEQPRPSTSKAVSPPHLDGPPSPRSPVIGSEVFLPNSNHVASGAGEAEERVVVISSSEDSDAENSSSRELDDSSSESSDLQLEGPSTLRVLDENLADPQAEDRPLVFFDLKIDNETQKISQLAAVNRESKFRVVIQPEAFFSIYSKAVSLEVGLQHFLSFLSSMRRPILACYKLWGPGLPNFFRALEDINRLWEFQEAISGFLAALPLIRERVPGASSFKLKNLAQTYLARNMSERSAMAAVLAMRDLCRLLEVSPGPQLAQHVYPFSSLQCFASLQPLVQAAVLPRAEARLLALHNVSFMELLSAHRRDRQGGLKKYSRYLSLQTTTLPPAQPAFNLQALGTYFEGLLEGPALARAEGVSTPLAGRGLAERASQQS | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
8 | Phosphorylation | MEPAPARSPRPQQDP CCCCCCCCCCCCCCC | 27.63 | 23401153 | |
22 | Phosphorylation | PARPQEPTMPPPETP CCCCCCCCCCCCCCC | 41.37 | 29255136 | |
28 | Phosphorylation | PTMPPPETPSEGRQP CCCCCCCCCCCCCCC | 37.58 | 26657352 | |
30 | Phosphorylation | MPPPETPSEGRQPSP CCCCCCCCCCCCCCC | 61.17 | 26657352 | |
36 | Phosphorylation | PSEGRQPSPSPSPTE CCCCCCCCCCCCCCC | 29.67 | 29255136 | |
38 | Phosphorylation | EGRQPSPSPSPTERA CCCCCCCCCCCCCCC | 42.20 | 30266825 | |
40 | Phosphorylation | RQPSPSPSPTERAPA CCCCCCCCCCCCCCC | 49.11 | 29255136 | |
42 | Phosphorylation | PSPSPSPTERAPASE CCCCCCCCCCCCCCH | 42.30 | 30266825 | |
48 | Phosphorylation | PTERAPASEEEFQFL CCCCCCCCHHHHHHH | 44.47 | 29255136 | |
65 | Sumoylation | QQCQAEAKCPKLLPC HHHHHHHCCCCHHHH | 42.44 | - | |
65 | Sumoylation | QQCQAEAKCPKLLPC HHHHHHHCCCCHHHH | 42.44 | 9756909 | |
65 | Ubiquitination | QQCQAEAKCPKLLPC HHHHHHHCCCCHHHH | 42.44 | - | |
68 | Ubiquitination | QAEAKCPKLLPCLHT HHHHCCCCHHHHHHH | 72.61 | - | |
117 | Phosphorylation | ESLQRRLSVYRQIVD HHHHHHHHHHHHHHH | 18.45 | 12402044 | |
119 | Phosphorylation | LQRRLSVYRQIVDAQ HHHHHHHHHHHHHHH | 8.07 | 21712546 | |
160 | Sumoylation | EAHQWFLKHEARPLA HHHHHHHHHCCHHHH | 29.89 | - | |
160 | Sumoylation | EAHQWFLKHEARPLA HHHHHHHHHCCHHHH | 29.89 | 9756909 | |
173 | Phosphorylation | LAELRNQSVREFLDG HHHHCCHHHHHHHHC | 27.05 | 27080861 | |
183 | Ubiquitination | EFLDGTRKTNNIFCS HHHHCCCCCCCEECC | 56.28 | - | |
184 | Phosphorylation | FLDGTRKTNNIFCSN HHHCCCCCCCEECCC | 30.15 | 25307156 | |
190 | Phosphorylation | KTNNIFCSNPNHRTP CCCCEECCCCCCCCC | 44.57 | 25307156 | |
196 | Phosphorylation | CSNPNHRTPTLTSIY CCCCCCCCCCCCEEE | 17.05 | 21815630 | |
198 | Phosphorylation | NPNHRTPTLTSIYCR CCCCCCCCCCEEEEC | 41.89 | 30108239 | |
200 | Phosphorylation | NHRTPTLTSIYCRGC CCCCCCCCEEEECCC | 18.63 | 23312004 | |
201 | Phosphorylation | HRTPTLTSIYCRGCS CCCCCCCEEEECCCC | 18.05 | 28857561 | |
203 | Phosphorylation | TPTLTSIYCRGCSKP CCCCCEEEECCCCCC | 3.94 | 30631047 | |
208 | Phosphorylation | SIYCRGCSKPLCCSC EEEECCCCCCCHHHH | 39.88 | 24719451 | |
220 | Phosphorylation | CSCALLDSSHSELKC HHHHHHCCCCCHHCC | 29.89 | 28348404 | |
221 | Phosphorylation | SCALLDSSHSELKCD HHHHHCCCCCHHCCC | 30.60 | 28348404 | |
226 | Sumoylation | DSSHSELKCDISAEI CCCCCHHCCCHHHHH | 26.30 | - | |
226 | Sumoylation | DSSHSELKCDISAEI CCCCCHHCCCHHHHH | 26.30 | 17000644 | |
226 | Ubiquitination | DSSHSELKCDISAEI CCCCCHHCCCHHHHH | 26.30 | - | |
309 | Phosphorylation | DARYQRDYEEMASRL HHHHHHCHHHHHHHH | 18.91 | - | |
337 | Ubiquitination | SALVQRMKCYASDQE HHHHHHHCCCCCCHH | 26.70 | - | |
339 | Phosphorylation | LVQRMKCYASDQEVL HHHHHCCCCCCHHHH | 12.01 | 24719451 | |
341 | Phosphorylation | QRMKCYASDQEVLDM HHHCCCCCCHHHHHH | 17.22 | 24719451 | |
366 | Phosphorylation | LRQEEPQSLQAAVRT HHHCCCCHHHHHHHC | 32.91 | 28555341 | |
380 | Sumoylation | TDGFDEFKVRLQDLS CCCCCHHHHHHHHHH | 25.13 | - | |
380 | 2-Hydroxyisobutyrylation | TDGFDEFKVRLQDLS CCCCCHHHHHHHHHH | 25.13 | - | |
380 | Acetylation | TDGFDEFKVRLQDLS CCCCCHHHHHHHHHH | 25.13 | 26822725 | |
380 | Sumoylation | TDGFDEFKVRLQDLS CCCCCHHHHHHHHHH | 25.13 | 28112733 | |
380 | Ubiquitination | TDGFDEFKVRLQDLS CCCCCHHHHHHHHHH | 25.13 | 21963094 | |
380 (in isoform 1) | Ubiquitination | - | 25.13 | 21890473 | |
380 (in isoform 2) | Ubiquitination | - | 25.13 | 21890473 | |
380 (in isoform 3) | Ubiquitination | - | 25.13 | 21890473 | |
380 (in isoform 4) | Ubiquitination | - | 25.13 | 21890473 | |
380 (in isoform 5) | Ubiquitination | - | 25.13 | 21890473 | |
387 | Phosphorylation | KVRLQDLSSCITQGK HHHHHHHHHHHHCCC | 31.30 | 26074081 | |
388 | Phosphorylation | VRLQDLSSCITQGKD HHHHHHHHHHHCCCH | 19.48 | 26074081 | |
391 | Phosphorylation | QDLSSCITQGKDAAV HHHHHHHHCCCHHHH | 35.28 | 26074081 | |
394 | Acetylation | SSCITQGKDAAVSKK HHHHHCCCHHHHHCC | 34.08 | 26051181 | |
394 | Malonylation | SSCITQGKDAAVSKK HHHHHCCCHHHHHCC | 34.08 | 26320211 | |
394 | Sumoylation | SSCITQGKDAAVSKK HHHHHCCCHHHHHCC | 34.08 | 28112733 | |
394 | Ubiquitination | SSCITQGKDAAVSKK HHHHHCCCHHHHHCC | 34.08 | 23000965 | |
394 (in isoform 1) | Ubiquitination | - | 34.08 | 21890473 | |
394 (in isoform 2) | Ubiquitination | - | 34.08 | 21890473 | |
394 (in isoform 3) | Ubiquitination | - | 34.08 | 21890473 | |
394 (in isoform 4) | Ubiquitination | - | 34.08 | 21890473 | |
394 (in isoform 5) | Ubiquitination | - | 34.08 | 21890473 | |
394 | Ubiquitination | SSCITQGKDAAVSKK HHHHHCCCHHHHHCC | 34.08 | 21890473 | |
394 | Ubiquitination | SSCITQGKDAAVSKK HHHHHCCCHHHHHCC | 34.08 | 21890473 | |
394 | Ubiquitination | SSCITQGKDAAVSKK HHHHHCCCHHHHHCC | 34.08 | 21890473 | |
394 | Ubiquitination | SSCITQGKDAAVSKK HHHHHCCCHHHHHCC | 34.08 | 21890473 | |
394 | Ubiquitination | SSCITQGKDAAVSKK HHHHHCCCHHHHHCC | 34.08 | 21890473 | |
394 | Ubiquitination | SSCITQGKDAAVSKK HHHHHCCCHHHHHCC | 34.08 | 21890473 | |
394 | Ubiquitination | SSCITQGKDAAVSKK HHHHHCCCHHHHHCC | 34.08 | 21890473 | |
394 | Ubiquitination | SSCITQGKDAAVSKK HHHHHCCCHHHHHCC | 34.08 | 21890473 | |
394 | Ubiquitination | SSCITQGKDAAVSKK HHHHHCCCHHHHHCC | 34.08 | 21890473 | |
394 | Ubiquitination | SSCITQGKDAAVSKK HHHHHCCCHHHHHCC | 34.08 | 21890473 | |
394 | Ubiquitination | SSCITQGKDAAVSKK HHHHHCCCHHHHHCC | 34.08 | 21890473 | |
399 | Phosphorylation | QGKDAAVSKKASPEA CCCHHHHHCCCCHHH | 24.58 | 30108239 | |
400 | Sumoylation | GKDAAVSKKASPEAA CCHHHHHCCCCHHHH | 45.84 | - | |
400 | Sumoylation | GKDAAVSKKASPEAA CCHHHHHCCCCHHHH | 45.84 | - | |
400 | Ubiquitination | GKDAAVSKKASPEAA CCHHHHHCCCCHHHH | 45.84 | 23000965 | |
400 (in isoform 1) | Ubiquitination | - | 45.84 | 21890473 | |
400 (in isoform 2) | Ubiquitination | - | 45.84 | 21890473 | |
400 (in isoform 3) | Ubiquitination | - | 45.84 | 21890473 | |
400 (in isoform 4) | Ubiquitination | - | 45.84 | 21890473 | |
400 (in isoform 5) | Ubiquitination | - | 45.84 | 21890473 | |
401 | Sumoylation | KDAAVSKKASPEAAS CHHHHHCCCCHHHHC | 46.74 | 28112733 | |
401 | Ubiquitination | KDAAVSKKASPEAAS CHHHHHCCCCHHHHC | 46.74 | 22817900 | |
401 (in isoform 1) | Ubiquitination | - | 46.74 | 21890473 | |
401 (in isoform 11) | Ubiquitination | - | 46.74 | - | |
401 (in isoform 2) | Ubiquitination | - | 46.74 | 21890473 | |
401 (in isoform 3) | Ubiquitination | - | 46.74 | 21890473 | |
401 (in isoform 4) | Ubiquitination | - | 46.74 | 21890473 | |
401 (in isoform 5) | Ubiquitination | - | 46.74 | 21890473 | |
403 | Phosphorylation | AAVSKKASPEAASTP HHHHCCCCHHHHCCC | 31.95 | 29255136 | |
403 (in isoform 11) | Phosphorylation | - | 31.95 | 23927012 | |
403 (in isoform 12) | Phosphorylation | - | 31.95 | 23927012 | |
403 (in isoform 13) | Phosphorylation | - | 31.95 | 23927012 | |
403 (in isoform 14) | Phosphorylation | - | 31.95 | 22617229 | |
408 | Phosphorylation | KASPEAASTPRDPID CCCHHHHCCCCCCCC | 46.09 | 23401153 | |
408 (in isoform 11) | Phosphorylation | - | 46.09 | 26657352 | |
408 (in isoform 12) | Phosphorylation | - | 46.09 | 26657352 | |
408 (in isoform 13) | Phosphorylation | - | 46.09 | 26657352 | |
408 (in isoform 14) | Phosphorylation | - | 46.09 | 24719451 | |
409 | Phosphorylation | ASPEAASTPRDPIDV CCHHHHCCCCCCCCC | 20.02 | 29255136 | |
409 (in isoform 11) | Phosphorylation | - | 20.02 | 26657352 | |
409 (in isoform 12) | Phosphorylation | - | 20.02 | 26657352 | |
409 (in isoform 13) | Phosphorylation | - | 20.02 | 26657352 | |
409 (in isoform 14) | Phosphorylation | - | 20.02 | 21712546 | |
421 (in isoform 11) | Phosphorylation | - | 54.62 | 23927012 | |
421 (in isoform 12) | Phosphorylation | - | 54.62 | 23927012 | |
421 (in isoform 13) | Phosphorylation | - | 54.62 | 23927012 | |
423 (in isoform 11) | Phosphorylation | - | 62.38 | 23927012 | |
423 (in isoform 12) | Phosphorylation | - | 62.38 | 23927012 | |
423 (in isoform 13) | Phosphorylation | - | 62.38 | 23927012 | |
424 (in isoform 11) | Phosphorylation | - | 42.14 | 23927012 | |
424 (in isoform 12) | Phosphorylation | - | 42.14 | 23927012 | |
424 (in isoform 13) | Phosphorylation | - | 42.14 | 23927012 | |
425 (in isoform 11) | Phosphorylation | - | 4.54 | 27542207 | |
425 (in isoform 12) | Phosphorylation | - | 4.54 | 27542207 | |
425 (in isoform 13) | Phosphorylation | - | 4.54 | 27542207 | |
426 | Ubiquitination | PEEAERVKAQVQALG CHHHHHHHHHHHHHC | 39.04 | 21963094 | |
428 | Ubiquitination | EAERVKAQVQALGLA HHHHHHHHHHHHCCC | 23.34 | 22817900 | |
428 (in isoform 11) | Ubiquitination | - | 23.34 | - | |
430 | Ubiquitination | ERVKAQVQALGLAEA HHHHHHHHHHCCCCC | 20.84 | 22817900 | |
432 (in isoform 10) | Phosphorylation | - | 3.02 | - | |
432 (in isoform 11) | Phosphorylation | - | 3.02 | 22210691 | |
432 (in isoform 12) | Phosphorylation | - | 3.02 | 22210691 | |
432 (in isoform 13) | Phosphorylation | - | 3.02 | 22210691 | |
434 (in isoform 11) | Phosphorylation | - | 3.96 | 22210691 | |
434 (in isoform 12) | Phosphorylation | - | 3.96 | 22210691 | |
434 (in isoform 13) | Phosphorylation | - | 3.96 | 22210691 | |
442 | Ubiquitination | AEAQPMAVVQSVPGA CCCCCCEEEEECCCC | 3.07 | 24816145 | |
449 | Ubiquitination | VVQSVPGAHPVPVYA EEEECCCCCCCCEEE | 9.57 | 22817900 | |
458 | Phosphorylation | PVPVYAFSIKGPSYG CCCEEEEEEECCCCC | 18.41 | 24719451 | |
460 | Sumoylation | PVYAFSIKGPSYGED CEEEEEEECCCCCCC | 64.67 | 28112733 | |
460 | Ubiquitination | PVYAFSIKGPSYGED CEEEEEEECCCCCCC | 64.67 | 29967540 | |
463 | Phosphorylation | AFSIKGPSYGEDVSN EEEEECCCCCCCCCC | 55.21 | 28857561 | |
464 | Phosphorylation | FSIKGPSYGEDVSNT EEEECCCCCCCCCCC | 27.89 | 28857561 | |
469 | Phosphorylation | PSYGEDVSNTTTAQK CCCCCCCCCCCHHHH | 40.56 | 28857561 | |
470 | Phosphorylation | SYGEDVSNTTTAQKR CCCCCCCCCCHHHHH | 41.09 | 32645325 | |
471 | Phosphorylation | YGEDVSNTTTAQKRK CCCCCCCCCHHHHHC | 20.30 | 28857561 | |
472 | Phosphorylation | GEDVSNTTTAQKRKC CCCCCCCCHHHHHCC | 25.12 | 24043423 | |
473 | Phosphorylation | EDVSNTTTAQKRKCS CCCCCCCHHHHHCCC | 25.67 | 24043423 | |
476 | Acetylation | SNTTTAQKRKCSQTQ CCCCHHHHHCCCCCC | 51.89 | 25953088 | |
476 | Sumoylation | SNTTTAQKRKCSQTQ CCCCHHHHHCCCCCC | 51.89 | 28112733 | |
476 | Ubiquitination | SNTTTAQKRKCSQTQ CCCCHHHHHCCCCCC | 51.89 | 21906983 | |
476 (in isoform 1) | Ubiquitination | - | 51.89 | 21890473 | |
476 (in isoform 2) | Ubiquitination | - | 51.89 | 21890473 | |
476 (in isoform 3) | Ubiquitination | - | 51.89 | 21890473 | |
476 (in isoform 4) | Ubiquitination | - | 51.89 | 21890473 | |
476 (in isoform 5) | Ubiquitination | - | 51.89 | 21890473 | |
478 | Sumoylation | TTTAQKRKCSQTQCP CCHHHHHCCCCCCCC | 45.32 | 28112733 | |
478 | Ubiquitination | TTTAQKRKCSQTQCP CCHHHHHCCCCCCCC | 45.32 | 22817900 | |
479 | Phosphorylation | TTAQKRKCSQTQCPR CHHHHHCCCCCCCCC | 4.18 | 32142685 | |
480 | Phosphorylation | TAQKRKCSQTQCPRK HHHHHCCCCCCCCCC | 39.02 | 27794612 | |
482 | Phosphorylation | QKRKCSQTQCPRKVI HHHCCCCCCCCCCEE | 18.82 | 30242111 | |
487 | Sumoylation | SQTQCPRKVIKMESE CCCCCCCCEEECCCH | 33.19 | - | |
487 | Acetylation | SQTQCPRKVIKMESE CCCCCCCCEEECCCH | 33.19 | 22274616 | |
487 | Sumoylation | SQTQCPRKVIKMESE CCCCCCCCEEECCCH | 33.19 | 28112733 | |
490 | Sumoylation | QCPRKVIKMESEEGK CCCCCEEECCCHHHH | 39.33 | - | |
490 | Acetylation | QCPRKVIKMESEEGK CCCCCEEECCCHHHH | 39.33 | 12653403 | |
490 | Sumoylation | QCPRKVIKMESEEGK CCCCCEEECCCHHHH | 39.33 | 17000644 | |
490 | Ubiquitination | QCPRKVIKMESEEGK CCCCCEEECCCHHHH | 39.33 | 24816145 | |
493 | Phosphorylation | RKVIKMESEEGKEAR CCEEECCCHHHHHHH | 37.13 | 26657352 | |
497 | Sumoylation | KMESEEGKEARLARS ECCCHHHHHHHHHCC | 52.02 | - | |
497 | Acetylation | KMESEEGKEARLARS ECCCHHHHHHHHHCC | 52.02 | 26051181 | |
497 | Sumoylation | KMESEEGKEARLARS ECCCHHHHHHHHHCC | 52.02 | 28112733 | |
497 | Ubiquitination | KMESEEGKEARLARS ECCCHHHHHHHHHCC | 52.02 | 21906983 | |
497 (in isoform 1) | Ubiquitination | - | 52.02 | 21890473 | |
497 (in isoform 2) | Ubiquitination | - | 52.02 | 21890473 | |
497 (in isoform 3) | Ubiquitination | - | 52.02 | 21890473 | |
497 (in isoform 4) | Ubiquitination | - | 52.02 | 21890473 | |
497 (in isoform 5) | Ubiquitination | - | 52.02 | 21890473 | |
504 | Phosphorylation | KEARLARSSPEQPRP HHHHHHCCCCCCCCC | 44.64 | 22167270 | |
505 | Phosphorylation | EARLARSSPEQPRPS HHHHHCCCCCCCCCC | 27.23 | 25159151 | |
512 | Phosphorylation | SPEQPRPSTSKAVSP CCCCCCCCCCCCCCC | 46.74 | 20201521 | |
513 | Phosphorylation | PEQPRPSTSKAVSPP CCCCCCCCCCCCCCC | 36.61 | 23927012 | |
514 | Phosphorylation | EQPRPSTSKAVSPPH CCCCCCCCCCCCCCC | 23.97 | 20201521 | |
515 | Acetylation | QPRPSTSKAVSPPHL CCCCCCCCCCCCCCC | 53.55 | 18621739 | |
518 | Phosphorylation | PSTSKAVSPPHLDGP CCCCCCCCCCCCCCC | 37.26 | 29255136 | |
518 (in isoform 4) | Phosphorylation | - | 37.26 | 23927012 | |
527 | Phosphorylation | PHLDGPPSPRSPVIG CCCCCCCCCCCCCCC | 35.76 | 29255136 | |
527 (in isoform 4) | Phosphorylation | - | 35.76 | 23927012 | |
530 | Phosphorylation | DGPPSPRSPVIGSEV CCCCCCCCCCCCCEE | 27.23 | 29255136 | |
530 (in isoform 4) | Phosphorylation | - | 27.23 | 30266825 | |
535 | Phosphorylation | PRSPVIGSEVFLPNS CCCCCCCCEEECCCC | 21.33 | 30266825 | |
535 (in isoform 4) | Phosphorylation | - | 21.33 | 30266825 | |
542 | Phosphorylation | SEVFLPNSNHVASGA CEEECCCCCCCCCCC | 26.77 | 23927012 | |
542 (in isoform 4) | Phosphorylation | - | 26.77 | 23927012 | |
547 | Phosphorylation | PNSNHVASGAGEAEE CCCCCCCCCCCCCCC | 28.25 | 23927012 | |
547 (in isoform 4) | Phosphorylation | - | 28.25 | 22777824 | |
560 | Phosphorylation | EERVVVISSSEDSDA CCEEEEEECCCCCCC | 19.05 | 29255136 | |
560 (in isoform 2) | Phosphorylation | - | 19.05 | 30108239 | |
560 | Ubiquitination | EERVVVISSSEDSDA CCEEEEEECCCCCCC | 19.05 | 21890473 | |
560 | Ubiquitination | EERVVVISSSEDSDA CCEEEEEECCCCCCC | 19.05 | 21890473 | |
561 | Phosphorylation | ERVVVISSSEDSDAE CEEEEEECCCCCCCC | 26.99 | 29255136 | |
561 (in isoform 2) | Phosphorylation | - | 26.99 | 30108239 | |
562 | Phosphorylation | RVVVISSSEDSDAEN EEEEEECCCCCCCCC | 38.34 | 29255136 | |
562 (in isoform 2) | Phosphorylation | - | 38.34 | 30108239 | |
565 | Phosphorylation | VISSSEDSDAENSSS EEECCCCCCCCCCCC | 34.37 | 23401153 | |
565 (in isoform 2) | Phosphorylation | - | 34.37 | 30108239 | |
565 (in isoform 9) | Phosphorylation | - | 34.37 | 19651622 | |
570 | Phosphorylation | EDSDAENSSSRELDD CCCCCCCCCCCCCCC | 22.61 | 29255136 | |
570 (in isoform 2) | Phosphorylation | - | 22.61 | 30108239 | |
571 | Phosphorylation | DSDAENSSSRELDDS CCCCCCCCCCCCCCC | 45.02 | 29255136 | |
572 | Phosphorylation | SDAENSSSRELDDSS CCCCCCCCCCCCCCC | 29.60 | 29255136 | |
572 (in isoform 2) | Phosphorylation | - | 29.60 | 30108239 | |
578 | Phosphorylation | SSRELDDSSSESSDL CCCCCCCCCCCCCCC | 35.12 | 22115753 | |
579 | Phosphorylation | SRELDDSSSESSDLQ CCCCCCCCCCCCCCC | 45.15 | 22115753 | |
580 | Phosphorylation | RELDDSSSESSDLQL CCCCCCCCCCCCCCC | 45.51 | 22115753 | |
580 (in isoform 2) | Phosphorylation | - | 45.51 | 29116813 | |
582 | Phosphorylation | LDDSSSESSDLQLEG CCCCCCCCCCCCCCC | 30.97 | 22115753 | |
583 | Phosphorylation | DDSSSESSDLQLEGP CCCCCCCCCCCCCCC | 37.98 | 22115753 | |
583 (in isoform 2) | Phosphorylation | - | 37.98 | 25849741 | |
591 | Phosphorylation | DLQLEGPSTLRVLDE CCCCCCCCHHHCCCC | 51.43 | 22115753 | |
592 | Phosphorylation | LQLEGPSTLRVLDEN CCCCCCCHHHCCCCC | 23.01 | 22115753 | |
597 (in isoform 2) | Phosphorylation | - | 39.62 | - | |
613 (in isoform 9) | Phosphorylation | - | 9.30 | 27067055 | |
616 | Sumoylation | PLVFFDLKIDNETQK CEEEEEEEECCCHHH | 50.27 | - | |
616 | Sumoylation | PLVFFDLKIDNETQK CEEEEEEEECCCHHH | 50.27 | 17000644 | |
623 | Ubiquitination | KIDNETQKISQLAAV EECCCHHHHHHHHCC | 52.31 | 23000965 | |
623 (in isoform 1) | Ubiquitination | - | 52.31 | 21890473 | |
623 | Ubiquitination | KIDNETQKISQLAAV EECCCHHHHHHHHCC | 52.31 | 21890473 | |
625 | Phosphorylation | DNETQKISQLAAVNR CCCHHHHHHHHCCCC | 26.61 | 20068231 | |
637 (in isoform 9) | Phosphorylation | - | 26.06 | 27067055 | |
672 (in isoform 13) | Phosphorylation | - | 18.64 | 25106551 | |
715 (in isoform 3) | Phosphorylation | - | 33.09 | 25106551 | |
720 (in isoform 8) | Phosphorylation | - | 34.92 | 25106551 | |
722 | Phosphorylation | RERVPGASSFKLKNL HHHCCCCCCHHHHHH | 42.07 | 26437602 | |
723 | Phosphorylation | ERVPGASSFKLKNLA HHCCCCCCHHHHHHH | 26.35 | 27067055 | |
725 | Methylation | VPGASSFKLKNLAQT CCCCCCHHHHHHHHH | 61.57 | 54409323 | |
725 | Ubiquitination | VPGASSFKLKNLAQT CCCCCCHHHHHHHHH | 61.57 | - | |
727 | Methylation | GASSFKLKNLAQTYL CCCCHHHHHHHHHHH | 50.97 | 115975197 | |
727 | Ubiquitination | GASSFKLKNLAQTYL CCCCHHHHHHHHHHH | 50.97 | - | |
733 | Phosphorylation | LKNLAQTYLARNMSE HHHHHHHHHHCCCCH | 6.05 | 28509920 | |
739 | Phosphorylation | TYLARNMSERSAMAA HHHHCCCCHHHHHHH | 33.15 | 23403867 | |
742 | Phosphorylation | ARNMSERSAMAAVLA HCCCCHHHHHHHHHH | 20.53 | 23403867 | |
742 (in isoform 13) | Phosphorylation | - | 20.53 | 27251275 | |
746 (in isoform 13) | Phosphorylation | - | 5.47 | 27251275 | |
755 (in isoform 13) | Phosphorylation | - | 49.99 | 27251275 | |
758 (in isoform 13) | Phosphorylation | - | 45.61 | 27251275 | |
771 (in isoform 13) | Phosphorylation | - | 22.89 | 26657352 | |
785 (in isoform 3) | Phosphorylation | - | 4.66 | 27251275 | |
789 (in isoform 3) | Phosphorylation | - | 9.42 | 27251275 | |
790 (in isoform 8) | Phosphorylation | - | 1.72 | 27251275 | |
794 (in isoform 8) | Phosphorylation | - | 35.29 | 27251275 | |
798 (in isoform 3) | Phosphorylation | - | 3.87 | 27251275 | |
801 (in isoform 3) | Phosphorylation | - | 27.34 | 27251275 | |
803 (in isoform 8) | Phosphorylation | - | 3.04 | 27251275 | |
804 | Phosphorylation | LLALHNVSFMELLSA HHHHHCCCHHHHHHH | 24.96 | - | |
806 (in isoform 8) | Phosphorylation | - | 2.49 | 27251275 | |
814 (in isoform 3) | Phosphorylation | - | 33.33 | 26657352 | |
819 (in isoform 8) | Phosphorylation | - | 26.45 | 26657352 | |
828 | Phosphorylation | KKYSRYLSLQTTTLP HHHHHHCCCEECCCC | 14.97 | 27251275 | |
866 | Phosphorylation | LARAEGVSTPLAGRG HHHCCCCCCCCCCCH | 34.85 | 29255136 | |
867 | Phosphorylation | ARAEGVSTPLAGRGL HHCCCCCCCCCCCHH | 21.66 | 23401153 | |
872 | Methylation | VSTPLAGRGLAERAS CCCCCCCCHHHHHHH | 31.20 | 83364561 | |
879 | Phosphorylation | RGLAERASQQS---- CHHHHHHHHCC---- | 34.67 | 23312004 | |
882 | Phosphorylation | AERASQQS------- HHHHHHCC------- | 34.25 | 27067055 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
8 | S | Phosphorylation | Kinase | HIPK2 | Q9H2X6 | GPS |
8 | S | Phosphorylation | Kinase | HIPK2 | Q9H2X6 | Uniprot |
28 | T | Phosphorylation | Kinase | MAPK1 | P28482 | GPS |
28 | T | Phosphorylation | Kinase | MAPK3 | P27361 | GPS |
36 | S | Phosphorylation | Kinase | HIPK2 | Q9H2X6 | Uniprot |
36 | S | Phosphorylation | Kinase | MAPK1 | P28482 | GPS |
36 | S | Phosphorylation | Kinase | MAPK1 | P28482 | Uniprot |
36 | S | Phosphorylation | Kinase | MAPK3 | P27361 | GPS |
38 | S | Phosphorylation | Kinase | MAPK3 | P27361 | GPS |
38 | S | Phosphorylation | Kinase | HIPK2 | Q9H2X6 | Uniprot |
38 | S | Phosphorylation | Kinase | HIPK2 | Q9H2X6 | GPS |
38 | S | Phosphorylation | Kinase | MAPK1 | P28482 | Uniprot |
38 | S | Phosphorylation | Kinase | MAPK1 | P28482 | GPS |
40 | S | Phosphorylation | Kinase | MAPK3 | P27361 | GPS |
40 | S | Phosphorylation | Kinase | MAPK1 | P28482 | GPS |
117 | S | Phosphorylation | Kinase | CHEK2 | O96017 | GPS |
117 | S | Phosphorylation | Kinase | CHEK2 | O96017 | GPS |
117 | S | Phosphorylation | Kinase | CHEK2 | O96017 | Uniprot |
403 | S | Phosphorylation | Kinase | MAPK1 | P28482 | Uniprot |
403 | S | Phosphorylation | Kinase | ERK5 | Q13164 | PSP |
409 | T | Phosphorylation | Kinase | MAPK7 | Q13164 | GPS |
505 | S | Phosphorylation | Kinase | MAPK1 | P28482 | Uniprot |
518 | S | Phosphorylation | Kinase | CDK2 | P24941 | PSP |
518 | S | Phosphorylation | Kinase | CDK1 | P06493 | PSP |
527 | S | Phosphorylation | Kinase | MAPK1 | P28482 | GPS |
527 | S | Phosphorylation | Kinase | MAPK3 | P27361 | GPS |
530 | S | Phosphorylation | Kinase | MAPK1 | P28482 | GPS |
530 | S | Phosphorylation | Kinase | MAPK3 | P27361 | GPS |
560 | S | Phosphorylation | Kinase | CSNK2A1 | P68400 | GPS |
561 | S | Phosphorylation | Kinase | CSNK2A1 | P68400 | GPS |
562 | S | Phosphorylation | Kinase | CSNK2A1 | P68400 | GPS |
565 | S | Phosphorylation | Kinase | CSNK2A1 | P68400 | GPS |
- | K | Ubiquitination | E3 ubiquitin ligase | KLHL20 | Q9Y2M5 | PMID:31279627:21840486 |
- | K | Ubiquitination | E3 ubiquitin ligase | RNF4 | P78317 | PMID:18408733 |
- | K | Ubiquitination | E3 ubiquitin ligase | UBE3A | Q05086 | PMID:25231954 |
- | K | Ubiquitination | E3 ubiquitin ligase | SIAH1 | Q8IUQ4 | PMID:14645235 |
- | K | Ubiquitination | E3 ubiquitin ligase | SIAH2 | O43255 | PMID:14645235 |
- | K | Ubiquitination | E3 ubiquitin ligase | RNF111 | Q6ZNA4 | PMID:23530056 |
- | K | Ubiquitination | E3 ubiquitin ligase | UHRF1 | Q96T88 | PMID:22945642 |
- | K | Ubiquitination | E3 ubiquitin ligase | RNF8 | O76064 | PMID:23708797 |
- | K | Ubiquitination | E3 ubiquitin ligase | ICP0 | P08393 | PMID:22199232 |
Modified Location | Modified Residue | Modification | Function | Reference |
---|---|---|---|---|
6 | K | ubiquitylation |
| 9756909 |
6 | K | Sumoylation |
| 9756909 |
8 | S | Sumoylation |
| 19015637 |
8 | S | Phosphorylation |
| 19015637 |
11 | K | ubiquitylation |
| 18408734 |
11 | K | Sumoylation |
| 18408734 |
36 | S | Sumoylation |
| 23186163 |
36 | S | Phosphorylation |
| 23186163 |
38 | S | Sumoylation |
| 19015637 |
38 | S | Phosphorylation |
| 19015637 |
48 | K | ubiquitylation |
| 18298799 |
48 | K | Sumoylation |
| 18298799 |
65 | K | Sumoylation |
| 9756909 |
65 | K | Sumoylation |
| 9756909 |
65 | K | Sumoylation |
| 9756909 |
117 | S | Phosphorylation |
| 12402044 |
160 | K | Sumoylation |
| 9756909 |
160 | K | Sumoylation |
| 9756909 |
160 | K | Sumoylation |
| 9756909 |
403 | S | Phosphorylation |
| 17081983 |
487 | K | Acetylation |
| 18298799 |
487 | K | Acetylation |
| 18298799 |
490 | K | Sumoylation |
| 9756909 |
490 | K | Sumoylation |
| 9756909 |
505 | S | Phosphorylation |
| 22033920 |
518 | S | Phosphorylation |
| 17081983 |
518 | S | Phosphorylation |
| 17081983 |
518 | S | ubiquitylation |
| 17081983 |
527 | S | Phosphorylation |
| 17081983 |
530 | S | Phosphorylation |
| 17081983 |
565 | S | Phosphorylation |
| 17081983 |
565 | S | Phosphorylation |
| 17081983 |
565 | S | Sumoylation |
| 17081983 |
565 | S | ubiquitylation |
| 17081983 |
565 | S | ubiquitylation |
| 17081983 |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of PML_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
H00003 | Acute myeloid leukemia (AML) | |||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
D00094 | Tretinoin (JAN/USP/INN); Avita (TN); Renova (TN); Retin A (TN); Tretinoin (TN); Vesanoid (TN) | |||||
D02106 | Arsenic trioxide (JP16/USAN); Trisenox (TN) | |||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-530 AND THR-867, ANDMASS SPECTROMETRY. | |
"PML tumor suppressor is regulated by HIPK2-mediated phosphorylationin response to DNA damage."; Gresko E., Ritterhoff S., Sevilla-Perez J., Roscic A., Froebius K.,Kotevic I., Vichalkovski A., Hess D., Hemmings B.A., Schmitz M.L.; Oncogene 28:698-708(2009). Cited for: PHOSPHORYLATION AT SER-8 AND SER-38 BY HIPK2, AND INTERACTION WITHHIPK2. | |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-403; THR-409; SER-518;SER-527 AND SER-530, AND MASS SPECTROMETRY. | |
"Evaluation of the low-specificity protease elastase for large-scalephosphoproteome analysis."; Wang B., Malik R., Nigg E.A., Korner R.; Anal. Chem. 80:9526-9533(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-403 AND SER-504, ANDMASS SPECTROMETRY. | |
"Global proteomic profiling of phosphopeptides using electron transferdissociation tandem mass spectrometry."; Molina H., Horn D.M., Tang N., Mathivanan S., Pandey A.; Proc. Natl. Acad. Sci. U.S.A. 104:2199-2204(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-505 AND SER-512, ANDMASS SPECTROMETRY. | |
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-8; SER-403; SER-518;SER-527; SER-530; SER-535; SER-560; SER-561; SER-562 AND SER-565, ANDMASS SPECTROMETRY. | |
"PML-dependent apoptosis after DNA damage is regulated by thecheckpoint kinase hCds1/Chk2."; Yang S., Kuo C., Bisi J.E., Kim M.K.; Nat. Cell Biol. 4:865-870(2002). Cited for: FUNCTION IN DNA REPAIR, PHOSPHORYLATION AT SER-117 BY CHEK2, ANDINTERACTION WITH CHEK2. | |
Sumoylation | |
Reference | PubMed |
"Identification of three major sentrinization sites in PML."; Kamitani T., Kito K., Nguyen H.P., Wada H., Fukuda-Kamitani T.,Yeh E.T.H.; J. Biol. Chem. 273:26675-26682(1998). Cited for: SUMOYLATION AT LYS-65; LYS-160 AND LYS-490, MUTAGENESIS OF LYS-65;LYS-133; LYS-150; LYS-160 AND LYS-490, SUBCELLULAR LOCATION, ANDFUNCTION. | |
Ubiquitylation | |
Reference | PubMed |
"RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required forarsenic-induced PML degradation."; Tatham M.H., Geoffroy M.C., Shen L., Plechanovova A., Hattersley N.,Jaffray E.G., Palvimo J.J., Hay R.T.; Nat. Cell Biol. 10:538-546(2008). Cited for: POLYUBIQUITINATION AT LYS-380; LYS-400; LYS-401 AND LYS-476 BY RNF4,PROTEASOMAL DEGRADATION, AND SUMOYLATION. |